AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06353477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPs® 7630
Description: EPs® 7630 is an extract from the roots of Pelargonium sidoides, drug-extract ratio 1 : 8-10, extraction solvent ethanol 11% (w/w). The patients were divided into two groups: (i) group 1 received herbal drug EPs® 7630 by oral route \[Umca® solution; (3x10 drops; between 1-5 years of age, 3x20 drops; 6-12 years of age, 3x30 drops for children \&gt;12 years of age)\] for 7 days and (ii) group 2 (control group) did not receive any herbal medication. The medication was administered orally, at least 30 minutes before or after meals. Patients in both groups were prescribed paracetamol (10 mg/kg/dose, 4 times a day, maximum 4,000 mg/day.) as an antipyretic agent. Temperature measurement was made at home and in the hospital via the axillary route.
Study NCT01057537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polypill
Description: The polypill will be taken once/day in the form of a hard capsule, to be taken orally. There are two versions of the polypill (Red Heart Pill):~Version 1 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Atenolol 50mg; Version 2 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Hydrochlorothiazide 12.5mg.
Study NCT01057537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual cardiovascular medications
Description: Participants in the 'Usual Care' arm will continue to take the separate, individual medications prescribed by their usual doctor, e.g. aspirin, blood pressure lowering drugs, statins.
Study NCT02572375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Codeine Phosphate/Guaifenesin ER Tablet
Description: Provide two Codeine Phosphate and Guaifenesin ER Tablet every 12 hours for 6 1/2 days.
Study NCT02572375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Codeine Phosphate/Guaifenesin IR Tablet
Description: Provide one Codeine Phosphate and Guaifenesin IR Tablet every 4 hours for 6 1/2 days
Study NCT02044679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Study NCT02044679 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Study NCT01306903 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Super MOPS
Description: Super modified and optimized perfusion system Frankfurt
Study NCT06309732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: 6mg at each cycle
Study NCT06309732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dactinomycin
Description: 1mg/m2
Study NCT06309732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Doses are titrated against renal function. Dosage: 30 mins loading plus 12 hour infusion
Study NCT06309732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 90mg/m2 injection for infusion
Study NCT06309732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 50mg/m2
Study NCT05247541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Definity
Description: Definity (Lantheus Medical Imaging, N Billerica, MA) in 50 mL of saline infused over 5-10 minutes
Study NCT05247541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Definity
Description: Definity (Lantheus Medical Imaging, N Billerica, MA) in 50 mL of saline infused over 5-10 minutes
Study NCT02768285 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: APICAL PATENCY
Description: After determining the working length, a small and flexible size 10 K-file was inserted 1 mm beyond the WL.
Study NCT03224364 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: nonsolo LA
Description: This patient is scheduled to undergo nonsolo laparoscpic appendectomy.
Study NCT03224364 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: solo LA
Description: This patient is scheduled to undergo solo laparoscpic appendectomy.
Study NCT04838184 — intervention group
Intervention type: DEVICE
Intervention: Dental Implants (Straumann Roxolid® / SLActive®)
Description: In this study the 4 mm implants will be inserted in the area surrounding 36/46. The implant diameters will be defined based on the patient's situation.~In the interforaminal region, two implants of conventional length with a minimum of 10 mm will be inserted. The implant diameter and the length will be defined based on the patient's situation.
Study NCT03852784 — intervention group
Intervention type: OTHER
Intervention: Bone and joint infection with Streptococcus peumoniae
Description: description of the osteoarticular infection with Streptococcus peumoniae
Study NCT00954330 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lateral ligament surgery
Description: . The disrupted FTA or/and FC and superficial retinacular structures were repaired by using absorbable sutures. In case of avulsion from the bone, the ligament was reapproximated with the use of sutures that were passed through 2.0 millimeter drill-holes in the bone.
Study NCT00954330 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: functional treatment
Description: Twenty-six patients randomized to the functional treatment received a functional light-weight orthotic device (Air-Cast ankle brace, Summit, New Jersey) for 3 weeks. Full weight bearing was allowed. The ankle brace allowed dorsi- and plantarflexion but it restricted inversion and eversion of the ankle.
Study NCT00675064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK369796
Description: Anti-malarial
Study NCT03815747 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Intensity Focused Electromagnetic (HIFEM) Field Device
Description: The High-Intensity Focused Electromagnetic (HIFEM) Field device will be applied.
Study NCT00981721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib (RECENTIN TM, AZD2171)
Description: 20 mg or 30mg cediranib once on Days 1, then 20 mg or 30mg cediranib once daily from Days 8
Study NCT01520584 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamale
Description: men will receive the vitamale dietary supplement compared to a sham pill
Study NCT04942132 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral (CBT)
Description: Treatment includes a smartphone-delivered CBT program designed to improve the quality of life of individuals with chronic pain. The treatment is condensed in nine weeks, and contains the following modules or units of treatment: sleep quality, anxiety management, pain coping, medication use, physical conditioning, mood regulation, problem solving, decision-making and relationships with others. All the content and settings are written in Spanish.
Study NCT04451759 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI exploration
Description: ultra high field (7T) magnetic resonance imaging
Study NCT04451759 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRI exploration
Description: ultra high field (7T) magnetic resonance imaging
Study NCT00913510 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CIC using LoFric Primo
Description: Anticholinergic medication according to clinical practice and investigator´s judgement, either started at screening visit or continued from before study start, and start of CIC using LoFric Primo catheters, i.e. Drug + Device.
Study NCT00913510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticholinergic medication
Description: Anticholinergic medication according to clinical practice and investigator´s judgement, either started at screening visit or continued from before study start, i.e. Drug.
Study NCT00913510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticholinergic medication
Description: Anticholinergic medication according to clinical practice and investigator´s judgement, either started at screening visit or continued from before study start, i.e. Drug.
Study NCT02802293 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation
Description: The MagPro R30 is an advanced, high performance magnetic stimulator designed primarily for non-invasive clinical use. The non-invasive brain stimulation system will be used to deliver repetitive electromagnetic pulses in this research study's treatment of major depressive disorder.
Study NCT02802293 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: robotic arm
Description: This robotic system is based on a commercially available neurosurgical robot. The robot is mounted on a mobile (i.e. retractable wheels) cart which holds the robot controller and the TMS power supply and pulse-generation computer. The robotic system will be used for TMS coil positioning/targeting.
Study NCT02126319 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Affective preparation
Description: Forty five minute cognitive-affective preparation session, wherein individuals were encouraged to experience and self-assess their personal reactions to the information they had just received about their prostate cancer risk status, and to anticipate (pre-live) and role play their potential psychological reactions to normal and abnormal test results and associated follow-up diagnostic and management recommendations. Combined with standard Prostate Risk Assessment Program (Group Prostate Cancer Education Session, Individual Counseling, Screening feedback)
Study NCT02126319 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Health Education
Description: A general health educational comparison session administered by research staff in order to equate for factual content, time, and attention. Participants in this session received information of relevance to men at risk for Pca, focusing on recommendations for general health (i.e., diet, exercise, alcohol use, and smoking) and were encouraged to freely probe, explore, and discuss their own attitudes, beliefs, expectations, and feelings about these topics in an interactive format. Combined with standard Prostate Risk Assessment Program (Group Prostate Cancer Education Session, Individual Counseling, Screening feedback)
Study NCT00675064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo matching GSK369796
Study NCT00440466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epoetin alfa
Description: Continue pre-study once weekly dose of epoetin alfa for 36 weeks
Study NCT00440466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epoetin alfa
Description: Double the pre-study once weekly dose of epoetin alfa every 2 weeks for 36 wks
Study NCT00856609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Byetta (exenatide)
Description: Exenatide is an injectable medication
Study NCT00856609 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight loss
Description: Because response to weight loss
Study NCT00856609 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Metabolic Chamber
Description: The subject stays in the small room
Study NCT00856609 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03757507 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MultiSpectral Optoacoustic Tomography
Description: Multispectral Optoacoustic Tomography is a new emerging imaging technique which uses laser light to heat up molecules with a high pulsed laser. The molecules undergo thermal expansion and produces sound waves, which can be detected by special transducers. The device can pick up different signals in different wavelength to produce images with anatomic and biological information.
Study NCT01520584 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamale
Description: men will receive the vitamale dietary supplement compared to a sham pill
Study NCT04639908 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: interview with patient
Study NCT01154881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Insulin degludec (IDeg) injected s.c. (under the skin) once daily for 6 days in each treatment period. Each subject was randomly allocated to 2 out of 4 treatments.
Study NCT02281981 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: 333mg CurcuWin OAHTCUR002-2014
Study NCT02281981 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: OAHTCUR005-2014
Study NCT00440466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epoetin alfa
Description: Quadruple the pre-study once weekly dose of epoetin alfa every 4 weeks for 36 wk
Study NCT04442490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-217
Description: SAGE-217 oral capsules.
Study NCT04325906 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high flow nasal cannula (HFNC)
Description: HFNC will be initiated at 50 L/min (AIRVO2 or Optiflow, Fisher \&Paykel Health care Limited., Auckland, New Zealand) with temperature set at 37 oC. Nasal cannula size will be determined by the patient's nostril size (≤ 50%). FIO2 will be adjusted to maintain SpO2 at 92% to 95%. Flow and temperature will be adjusted based on patient's comfort and clinical response.
Study NCT04325906 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high flow nasal cannula (HFNC)
Description: HFNC will be initiated at 50 L/min (AIRVO2 or Optiflow, Fisher \&Paykel Health care Limited., Auckland, New Zealand) with temperature set at 37 oC. Nasal cannula size will be determined by the patient's nostril size (≤ 50%). FIO2 will be adjusted to maintain SpO2 at 92% to 95%. Flow and temperature will be adjusted based on patient's comfort and clinical response.
Study NCT04325906 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prone positioning (PP)
Description: PP will be performed before or 1 hour after meal. Before PP, all the I.V. lines and nasal cannula will be checked by clinicians. PP will be performed by patient under the supervision of clinicians. Assistance will be offered if needed. If tolerated, PP will be maintained for at least 30 minutes, until the patients feel tired to keep that position. PP will be performed twice a day for the first 3 days after the patient's enrollment. FIO2 will be adjusted to maintain SpO2 at 92-95%.
Study NCT04752943 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tips By Text Messages
Description: Texts sent to caregivers meant to increase parent child interaction around literacy, sent to participants 3 x a week for 7 months
Study NCT04442490 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SAGE-217 matched-placebo oral capsules.
Study NCT04467268 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep extension
Description: The sleep extension programme was designed around four alternative assumptions: 1) that among this group of habitual short sleepers, extending time in bed (TIB) would represent a significant behavioral change to established night-time and daytime routines; 2) that for practical purposes (accommodating personal, family and work schedules) extended time in bed is best anchored against typical rise-times; 3) that sleep onset may represent a particular challenge for those advancing habitual bed-times by over 1 hour each night; and 4) that in consenting to the trial, participants were motivated to make and sustain behavioral change.
Study NCT02751970 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental restoration
Description: Methacrylate resins will be used to complement the cavity restoration after of adhesive procedure
Study NCT02751970 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental restoration
Description: Methacrylate resins will be used to complement the cavity restoration after of adhesive procedure
Study NCT02751970 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3 step ER
Description: Enamel and dentin will be conditioning with 35% phosphoric acid, then applied primer, and then applied adhesive resin.
Study NCT02751970 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2 step ER
Description: Enamel and dentin will be conditioning with 35% of phosphoric acid, then applied primer/adhesive resin.
Study NCT02751970 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 2 step SE
Description: Enamel and dentin will be conditioning with acidic primer, then applied primer/adhesive resin.
Study NCT02751970 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 1 step SE
Description: Enamel and dentin will be conditioning with acidic primer/adhesive resin.
Study NCT02568566 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02568566 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human Papillomavirus Nonavalent Vaccine
Description: Given IM
Study NCT04868383 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of smart phone technology to support medication adherence and uptake
Description: Use of smart phone technology to support medication adherence and uptake
Study NCT00373607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisin-piperaquine
Description: Dihydroartemisin-piperaquine (Artekin) manufactured by Hualijian Pharmaceutical Co. Ltd., Guangzhou, China. Each tablet contains 40mg of dihydroartemisinin and 320mg piperaquine
Study NCT00373607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mefloquine + Artesunate
Description: Mefloquine + Artesunate (MAS3). The regimen is artesunate 4 mg/kg/day once daily for 3 days plus mefloquine 24 mg/kg given as a three day regimen of 8mg/kg/day
Study NCT01333410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus ointment
Description: 2 applications per days for 6 months
Study NCT01333410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone furoate
Description: 2 applications per day for 6 months
Study NCT00439335 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Influenza A Vaccine A/H5N1
Description: Inactivated influenza A/H5N1 vaccine formulated to a concentration of HA greater than or equal to 300 mcg/mL administered via intramuscular (IM) injection. Vaccine will be administered to each subject at Days 0 and 28.
Study NCT00439335 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Influenza A Vaccine A/H5N1
Description: Inactivated influenza A/H5N1 vaccine formulated to a concentration of HA greater than or equal to 300 mcg/mL administered via intradermal (ID) injection. Vaccine will be administered to each subject at Days 0 and 28.
Study NCT00439335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (IM)
Description: The placebo will be 0.1 mL of saline administered by the IM route.
Study NCT00439335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (ID)
Description: The placebo will be 0.1 mL of saline administered by the ID route.
Study NCT00848458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iontophoresis
Description: iontophoresis with 15% azelaic acid gel twice weekly
Study NCT00848458 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Azelaic acid cream
Description: topical treatment with 20% azelaic acid cream twice daily
Study NCT01969539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combivent Respimat via tee adapter
Description: Patients (all); previously intubated and ventilated; in need of bronchodilation w/CVT-R via tee adapter
Study NCT01969539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combivent Respimat via ventilator adapter
Description: Patients (all); previously intubated and ventilated; in need of bronchodilation w/CVT-R via ventilator adapter
Study NCT01482195 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Subretinal administration of rAAV2-VMD2-hMERTKRecombinant Adeno-Associated Virus
Description: The study is an open-label, dose-escalation, phase I clinical trial of subretinal administration of rAAV2-VMD2-hMERTK in patients with retinitis pigmentosa due to MERTK mutation.
Study NCT04469205 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coaching sessions
Description: There are 3 sessions : the first session will last 1h30 and will be in consultation within the Institut Curie. The second session will last 1h30 and will be done remotely (by phone or by videoconference). The duration of the 3rd and last session will be adapted according to the needs of each patient and will last a maximum of 1 hour. It will also be done remotely (by phone or by videoconference).
Study NCT02307240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CUDC-907
Description: CUDC-907 oral with meals.
Study NCT02533310 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OST treatment with in-vivo spiders
Description: Subjects are exposed to phobic stimuli with the aid of a trained psychotherapist during a session of maximum 3 hrs duration. The intensity of exposure is increased in four sequential steps, 1. learning to catch a spider with a glass and paper, 2. touching a spider, 3. letting a spider walk on your hand, 4. letting a spider walk on your body. These stages repeat with increasingly larger spiders. The goal of therapy is not absolute symptom reduction but sufficient reduction to allow the individual to expose themselves in everyday situations.
Study NCT02533310 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR-OST treatment with virtual spiders
Description: The VR-OST treatment introduces a virtual gamified version of OST treatment using a modern virtual reality headset. Individuals advance themselves through increasing levels of exposure intensity with the assistance of an automated virtual therapist.